ANTICHOLESTEROL statin medications are saving lives, with patients on higher doses gaining the most benefit, according to a recent "real-world practice" study published in JAMA Cardiology.
More than half a million patients with atherosclerotic cardiovascular disease and an average age of 69 years being treated with varying doses of atorvastatin, rosuvastatin, simvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin or controls, were evaluated for longevity.
High-intensity statins, namely atorvastatin (originally Lipitor from Pfizer) 80 mg and rosuvastatin (originally Crestor from AstraZeneca) 40 mg, conferred the greatest survival advantage compared with submaximal doses of high-intensity statins.
CLICK HERE to access the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Nov 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 16
